Trial abstract · §3
DREAMS-3 — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Change in glycated haemoglobin from baseline against an active comparator | no result held by the Institute | Not rated |
| The Institute publishes no effect estimate for a trial whose report it does not hold. | ||
§3.2Harms as reported
Table 5. Adverse events for Mazdutide from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Nausea | 32.0 | 8.0 | Phase 3 obesity (6 mg) |
| Diarrhoea | 22.0 | 9.0 | Phase 3 obesity |
| Vomiting | 16.0 | 2.0 | Phase 3 obesity |
| Increased heart rate | — | — | Reported; attributed to the glucagon arm |
| Discontinuation for adverse events | 5.0 | 2.0 | Phase 3 obesity |
Compound Evidence Institute · CEI-TR-0138/3 · https://compoundevidence.com/trials/dreams-3/results/ · retrieved 30 July 2026